Phaseline

Companies › Nefro Avillion Clinical Development

Nefro Avillion Clinical Development: clinical trials, targets and expected readouts

1 active drug program in 4 registered trials: 3 Phase 1, 1 Phase 2; Gastroenterology, Genitourinary; next expected readout Mar 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Siplizumab
T-cell surface antigen CD2 inhibitor
CD2Phase 2Renal Transplant Failure and Rejection; Autoimmune Liver Disease; Renal Failure; Kidney FailureMar 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06455280SiplizumabPhase 1Autoimmune Liver DiseaseGastroenterologyDec 2027
NCT07508787SiplizumabPhase 2Renal Transplant Failure and RejectionGenitourinaryMar 2028
NCT04540380SiplizumabPhase 1Renal FailureGenitourinaryJan 2029
NCT05900401SiplizumabPhase 1Kidney FailureGenitourinaryDec 2031

Targets

CD2 (1)

Companies with the same targets

ITB-Med

Companies built like this

Singulera Therapeutics Yaqrit Cerium Pharmaceuticals Noorik Biopharmaceuticals TLC Biopharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.